


National Institute on Aging

(Fiscal Years 2003 – 2009)

Funding Levels in Current and FY 2003 Constant Dollars

Percent change (estimated) current dollars: **+5.0%**

Percent change (estimated) constant dollars: **-12.9%**




* **Current dollars** - dollar value of a good or service in terms of prices prevailing at the time the good was sold or service rendered.

* **Constant dollars** - dollar value adjusted for inflation to demonstrate "real" increases. Determined by dividing current dollars by an appropriate price index, a process generally known as "deflating."


National Institute on Aging

FY 2009 President's Budget - \$1,048,278,000

(Dollars in thousands)



National Institute on Aging Research Project Grant Success Rates* Fiscal Years 1999-2009



* Success rate: The success rate is the proportion of applications reviewed that is actually awarded.

** Beginning in FY 1994. SBIR and STTR applications are not included in success rate calculations.

Success Rates

FY	NIA	NIH Average
2004	20.8	25.0
2005	18.8	22.0
2006	17.4	20.0
2007	22.1	21.0
2008 est.	19.9	19.0
2009 est.	23.1	18.0

NIH Financial Policy for Grant Awards - FY 2009

Research Project Grants (RPGs)

Non-competing awards - No inflationary increases are provided for direct recurring costs. Where NIA has committed to a programmatic increase for an award, such increase will be provided.

The amounts provided for competing RPGs will be managed to an average award amount equal to FY 2008 levels.

Research Training – Stipend levels will be increased by .1 percent.

NIA Policy for New Investigators

- R01 applications from new investigators will be considered among NIA's highest priorities in the use of discretionary funds to make awards selectively. Therefore, such applications may be funded out of strict percentile order. Currently R01 applications from new investigators within five points of the payline may be selected for payment.

**National Institute on Aging
Impact of Cost Management Policies
On a Single R01 Grant Competing In FY 2005**

	FY 2005								
	FY 2005 Recommended	After NIA Total Cost Reductions	FY 2006	FY 2007	FY 2008 Est.	FY 2009 Est.	Total Project Period	\$ Reduction from Rec. Costs	% Reduction from Rec. Costs
Full Recommended Costs*	\$350,000	\$350,000	\$360,500	\$371,315	\$382,454	\$393,928	\$1,858,197		
Policy FY 2004-2005**	350,000	287,000	295,610	304,478	313,612	323,020	1,523,720	\$334,477	-18.0%
Policy FY 2006-2008***	350,000	287,000	287,000	287,000	289,870	289,870	1,440,740	417,457	-22.5%


* Awarded at recommended levels with annual inflationary increases for recurring costs.

** Awarded with 18% average reductions from IRG recommended levels in first year with 3% annual inflation increases for recurring costs in future years.

*** Awarded with 18% average reductions from recommended levels in first year with no annual inflationary increases for recurring costs in FYs 2006 and 2007. FY 2008 provides a 1% inflationary increase and FY 2009 is flat.


National Institutes of Health Alzheimer's Disease Research

Dollars in Millions



National Institutes of Health Alzheimer's Disease Research

Dollars in Millions



Funding Opportunities

- RFA-AG-09-002 Biomarkers for Older Controls at Risk for Dementia (BIOCARD) (U01)
- RFA-AG-09-001 Alzheimer's Disease Research Centers (P50)
- RFA-AG-08-002 International Network for Identification, Evaluation, and F/U of Families w/Early Onset Dominantly Inherited AD (U01)
- RFA-AG-08-001 Protein Homeostasis in Aging: Repair & Degradation (R21)
- RFA-AG-08-006 Paul B. Beeson Career Development Awards in Aging (K08/K23)

Markey Awards/Beeson Scholars

Grant #	PI	Topic	Mentor
K08AG028977	Fisher	Dopamine, Tyrosine, and Metabolites in Aging in Neurodegenerative DZ	Greenamyre
K08AG029147	Donahue	Effects of ApoE Genotype on Blood Brain Barrier Permeability	Stopa
K23AG026768	Wilkins	Vitamin D in Older Adults: Cognition, Mood & Hippocampal Volume	Morris
K23AG030935	Kantarci	MRS Markers of MCI Syndromes & Common Dementias	Petersen
K23AG030946	Bateman	Proteomic Analysis of CSF in AD & Aging	Holtzman
K23AG028982	Wang	FMRI: Prediction of MCI in Mild Depression	Steffens